The Neuroendocrine Tumor Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Neuroendocrine Tumor Drug market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Neuroendocrine Tumor Drug global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While mTOR Protein Inhibitors segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Neuroendocrine Tumor Drug include Eisai, Exelixis, Inc., Foresee Pharmaceuticals, LLC, Hutchison MediPharma Limited, and Intezyne, Inc, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Neuroendocrine Tumor Drug market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
- mTOR Protein Inhibitors
- Tyrosine Kinase 3 Inhibitors
- Somatostatin Receptor Antagonists
- Growth Hormone Releasing Factor Antagonists
- Somatostatin Receptor Agonists
- Others
Market segment by Application can be divided into
- Hospital
- Clinic
- Others
The key market players for global Neuroendocrine Tumor Drug market are listed below:
- Eisai
- Exelixis, Inc.
- Foresee Pharmaceuticals, LLC
- Hutchison MediPharma Limited
- Intezyne, Inc
- INVENT Pharmaceuticals, Inc.
- Ipsen S.A.
- Jiangsu Hengrui Medicine Co., Ltd.
- Karyopharm Therapeutics, Inc.
- Lexicon Pharmaceuticals, Inc.
- Midatech Pharma Plc .
- Millennium Pharmaceuticals, Inc.
- MolMed S.p.A.
- Northwest Biotherapeutics, Inc.
- Novartis AG
- OctreoPharm Sciences GmbH
- OXiGENE, Inc.
Market segment by region, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neuroendocrine Tumor Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neuroendocrine Tumor Drug, with price, sales, revenue and global market share of Neuroendocrine Tumor Drug from 2019 to 2022.
Chapter 3, the Neuroendocrine Tumor Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuroendocrine Tumor Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Neuroendocrine Tumor Drug market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neuroendocrine Tumor Drug.
Chapter 13, 14, and 15, to describe Neuroendocrine Tumor Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Global Neuroendocrine Tumor Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028
Table of Contents
1 Market Overview
1.1 Neuroendocrine Tumor Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neuroendocrine Tumor Drug Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 mTOR Protein Inhibitors
1.2.3 Tyrosine Kinase 3 Inhibitors
1.2.4 Somatostatin Receptor Antagonists
1.2.5 Growth Hormone Releasing Factor Antagonists
1.2.6 Somatostatin Receptor Agonists
1.2.7 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Neuroendocrine Tumor Drug Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Neuroendocrine Tumor Drug Market Size & Forecast
1.4.1 Global Neuroendocrine Tumor Drug Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Neuroendocrine Tumor Drug Sales in Volume (2017-2028)
1.4.3 Global Neuroendocrine Tumor Drug Price (2017-2028)
1.5 Global Neuroendocrine Tumor Drug Production Capacity Analysis
1.5.1 Global Neuroendocrine Tumor Drug Total Production Capacity (2017-2028)
1.5.2 Global Neuroendocrine Tumor Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Neuroendocrine Tumor Drug Market Drivers
1.6.2 Neuroendocrine Tumor Drug Market Restraints
1.6.3 Neuroendocrine Tumor Drug Trends Analysis
2 Manufacturers Profiles
2.1 Eisai
2.1.1 Eisai Details
2.1.2 Eisai Major Business
2.1.3 Eisai Neuroendocrine Tumor Drug Product and Services
2.1.4 Eisai Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Exelixis, Inc.
2.2.1 Exelixis, Inc. Details
2.2.2 Exelixis, Inc. Major Business
2.2.3 Exelixis, Inc. Neuroendocrine Tumor Drug Product and Services
2.2.4 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Foresee Pharmaceuticals, LLC
2.3.1 Foresee Pharmaceuticals, LLC Details
2.3.2 Foresee Pharmaceuticals, LLC Major Business
2.3.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product and Services
2.3.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Hutchison MediPharma Limited
2.4.1 Hutchison MediPharma Limited Details
2.4.2 Hutchison MediPharma Limited Major Business
2.4.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product and Services
2.4.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Intezyne, Inc
2.5.1 Intezyne, Inc Details
2.5.2 Intezyne, Inc Major Business
2.5.3 Intezyne, Inc Neuroendocrine Tumor Drug Product and Services
2.5.4 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 INVENT Pharmaceuticals, Inc.
2.6.1 INVENT Pharmaceuticals, Inc. Details
2.6.2 INVENT Pharmaceuticals, Inc. Major Business
2.6.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product and Services
2.6.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Ipsen S.A.
2.7.1 Ipsen S.A. Details
2.7.2 Ipsen S.A. Major Business
2.7.3 Ipsen S.A. Neuroendocrine Tumor Drug Product and Services
2.7.4 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Jiangsu Hengrui Medicine Co., Ltd.
2.8.1 Jiangsu Hengrui Medicine Co., Ltd. Details
2.8.2 Jiangsu Hengrui Medicine Co., Ltd. Major Business
2.8.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product and Services
2.8.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Karyopharm Therapeutics, Inc.
2.9.1 Karyopharm Therapeutics, Inc. Details
2.9.2 Karyopharm Therapeutics, Inc. Major Business
2.9.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product and Services
2.9.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Lexicon Pharmaceuticals, Inc.
2.10.1 Lexicon Pharmaceuticals, Inc. Details
2.10.2 Lexicon Pharmaceuticals, Inc. Major Business
2.10.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product and Services
2.10.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Midatech Pharma Plc .
2.11.1 Midatech Pharma Plc . Details
2.11.2 Midatech Pharma Plc . Major Business
2.11.3 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product and Services
2.11.4 Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Millennium Pharmaceuticals, Inc.
2.12.1 Millennium Pharmaceuticals, Inc. Details
2.12.2 Millennium Pharmaceuticals, Inc. Major Business
2.12.3 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product and Services
2.12.4 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 MolMed S.p.A.
2.13.1 MolMed S.p.A. Details
2.13.2 MolMed S.p.A. Major Business
2.13.3 MolMed S.p.A. Neuroendocrine Tumor Drug Product and Services
2.13.4 MolMed S.p.A. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Northwest Biotherapeutics, Inc.
2.14.1 Northwest Biotherapeutics, Inc. Details
2.14.2 Northwest Biotherapeutics, Inc. Major Business
2.14.3 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product and Services
2.14.4 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15 Novartis AG
2.15.1 Novartis AG Details
2.15.2 Novartis AG Major Business
2.15.3 Novartis AG Neuroendocrine Tumor Drug Product and Services
2.15.4 Novartis AG Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16 OctreoPharm Sciences GmbH
2.16.1 OctreoPharm Sciences GmbH Details
2.16.2 OctreoPharm Sciences GmbH Major Business
2.16.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product and Services
2.16.4 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17 OXiGENE, Inc.
2.17.1 OXiGENE, Inc. Details
2.17.2 OXiGENE, Inc. Major Business
2.17.3 OXiGENE, Inc. Neuroendocrine Tumor Drug Product and Services
2.17.4 OXiGENE, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Neuroendocrine Tumor Drug Breakdown Data by Manufacturer
3.1 Global Neuroendocrine Tumor Drug Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Neuroendocrine Tumor Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Neuroendocrine Tumor Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Neuroendocrine Tumor Drug Manufacturer Market Share in 2021
3.4.2 Top 6 Neuroendocrine Tumor Drug Manufacturer Market Share in 2021
3.5 Global Neuroendocrine Tumor Drug Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Neuroendocrine Tumor Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Neuroendocrine Tumor Drug Market Size by Region
4.1.1 Global Neuroendocrine Tumor Drug Sales in Volume by Region (2017-2028)
4.1.2 Global Neuroendocrine Tumor Drug Revenue by Region (2017-2028)
4.2 North America Neuroendocrine Tumor Drug Revenue (2017-2028)
4.3 Europe Neuroendocrine Tumor Drug Revenue (2017-2028)
4.4 Asia-Pacific Neuroendocrine Tumor Drug Revenue (2017-2028)
4.5 South America Neuroendocrine Tumor Drug Revenue (2017-2028)
4.6 Middle East and Africa Neuroendocrine Tumor Drug Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Neuroendocrine Tumor Drug Sales in Volume by Type (2017-2028)
5.2 Global Neuroendocrine Tumor Drug Revenue by Type (2017-2028)
5.3 Global Neuroendocrine Tumor Drug Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Neuroendocrine Tumor Drug Sales in Volume by Application (2017-2028)
6.2 Global Neuroendocrine Tumor Drug Revenue by Application (2017-2028)
6.3 Global Neuroendocrine Tumor Drug Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Neuroendocrine Tumor Drug Sales by Type (2017-2028)
7.2 North America Neuroendocrine Tumor Drug Sales by Application (2017-2028)
7.3 North America Neuroendocrine Tumor Drug Market Size by Country
7.3.1 North America Neuroendocrine Tumor Drug Sales in Volume by Country (2017-2028)
7.3.2 North America Neuroendocrine Tumor Drug Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Neuroendocrine Tumor Drug Sales by Type (2017-2028)
8.2 Europe Neuroendocrine Tumor Drug Sales by Application (2017-2028)
8.3 Europe Neuroendocrine Tumor Drug Market Size by Country
8.3.1 Europe Neuroendocrine Tumor Drug Sales in Volume by Country (2017-2028)
8.3.2 Europe Neuroendocrine Tumor Drug Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Neuroendocrine Tumor Drug Sales by Type (2017-2028)
9.2 Asia-Pacific Neuroendocrine Tumor Drug Sales by Application (2017-2028)
9.3 Asia-Pacific Neuroendocrine Tumor Drug Market Size by Region
9.3.1 Asia-Pacific Neuroendocrine Tumor Drug Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Neuroendocrine Tumor Drug Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Neuroendocrine Tumor Drug Sales by Type (2017-2028)
10.2 South America Neuroendocrine Tumor Drug Sales by Application (2017-2028)
10.3 South America Neuroendocrine Tumor Drug Market Size by Country
10.3.1 South America Neuroendocrine Tumor Drug Sales in Volume by Country (2017-2028)
10.3.2 South America Neuroendocrine Tumor Drug Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Neuroendocrine Tumor Drug Sales by Type (2017-2028)
11.2 Middle East & Africa Neuroendocrine Tumor Drug Sales by Application (2017-2028)
11.3 Middle East & Africa Neuroendocrine Tumor Drug Market Size by Country
11.3.1 Middle East & Africa Neuroendocrine Tumor Drug Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Neuroendocrine Tumor Drug Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Neuroendocrine Tumor Drug and Key Manufacturers
12.2 Manufacturing Costs Percentage of Neuroendocrine Tumor Drug
12.3 Neuroendocrine Tumor Drug Production Process
12.4 Neuroendocrine Tumor Drug Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Neuroendocrine Tumor Drug Typical Distributors
13.3 Neuroendocrine Tumor Drug Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
List of Tables
Table 1. Global Neuroendocrine Tumor Drug Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Neuroendocrine Tumor Drug Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Eisai Basic Information, Manufacturing Base and Competitors
Table 4. Eisai Major Business
Table 5. Eisai Neuroendocrine Tumor Drug Product and Services
Table 6. Eisai Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Exelixis, Inc. Basic Information, Manufacturing Base and Competitors
Table 8. Exelixis, Inc. Major Business
Table 9. Exelixis, Inc. Neuroendocrine Tumor Drug Product and Services
Table 10. Exelixis, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Foresee Pharmaceuticals, LLC Basic Information, Manufacturing Base and Competitors
Table 12. Foresee Pharmaceuticals, LLC Major Business
Table 13. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product and Services
Table 14. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Hutchison MediPharma Limited Basic Information, Manufacturing Base and Competitors
Table 16. Hutchison MediPharma Limited Major Business
Table 17. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product and Services
Table 18. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Intezyne, Inc Basic Information, Manufacturing Base and Competitors
Table 20. Intezyne, Inc Major Business
Table 21. Intezyne, Inc Neuroendocrine Tumor Drug Product and Services
Table 22. Intezyne, Inc Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. INVENT Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 24. INVENT Pharmaceuticals, Inc. Major Business
Table 25. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product and Services
Table 26. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Ipsen S.A. Basic Information, Manufacturing Base and Competitors
Table 28. Ipsen S.A. Major Business
Table 29. Ipsen S.A. Neuroendocrine Tumor Drug Product and Services
Table 30. Ipsen S.A. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Jiangsu Hengrui Medicine Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 32. Jiangsu Hengrui Medicine Co., Ltd. Major Business
Table 33. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product and Services
Table 34. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Karyopharm Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 36. Karyopharm Therapeutics, Inc. Major Business
Table 37. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product and Services
Table 38. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Lexicon Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 40. Lexicon Pharmaceuticals, Inc. Major Business
Table 41. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product and Services
Table 42. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Midatech Pharma Plc . Basic Information, Manufacturing Base and Competitors
Table 44. Midatech Pharma Plc . Major Business
Table 45. Midatech Pharma Plc . Neuroendocrine Tumor Drug Product and Services
Table 46. Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Millennium Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 48. Millennium Pharmaceuticals, Inc. Major Business
Table 49. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product and Services
Table 50. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. MolMed S.p.A. Basic Information, Manufacturing Base and Competitors
Table 52. MolMed S.p.A. Major Business
Table 53. MolMed S.p.A. Neuroendocrine Tumor Drug Product and Services
Table 54. MolMed S.p.A. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 55. Northwest Biotherapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 56. Northwest Biotherapeutics, Inc. Major Business
Table 57. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product and Services
Table 58. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 59. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 60. Novartis AG Major Business
Table 61. Novartis AG Neuroendocrine Tumor Drug Product and Services
Table 62. Novartis AG Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 63. OctreoPharm Sciences GmbH Basic Information, Manufacturing Base and Competitors
Table 64. OctreoPharm Sciences GmbH Major Business
Table 65. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product and Services
Table 66. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 67. OXiGENE, Inc. Basic Information, Manufacturing Base and Competitors
Table 68. OXiGENE, Inc. Major Business
Table 69. OXiGENE, Inc. Neuroendocrine Tumor Drug Product and Services
Table 70. OXiGENE, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 71. Global Neuroendocrine Tumor Drug Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Pcs)
Table 72. Global Neuroendocrine Tumor Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 73. Market Position of Manufacturers in Neuroendocrine Tumor Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 74. Global Neuroendocrine Tumor Drug Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 75. Head Office and Neuroendocrine Tumor Drug Production Site of Key Manufacturer
Table 76. Neuroendocrine Tumor Drug New Entrant and Capacity Expansion Plans
Table 77. Neuroendocrine Tumor Drug Mergers & Acquisitions in the Past Five Years
Table 78. Global Neuroendocrine Tumor Drug Sales by Region (2017-2022) & (K Pcs)
Table 79. Global Neuroendocrine Tumor Drug Sales by Region (2023-2028) & (K Pcs)
Table 80. Global Neuroendocrine Tumor Drug Revenue by Region (2017-2022) & (USD Million)
Table 81. Global Neuroendocrine Tumor Drug Revenue by Region (2023-2028) & (USD Million)
Table 82. Global Neuroendocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 83. Global Neuroendocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 84. Global Neuroendocrine Tumor Drug Revenue by Type (2017-2022) & (USD Million)
Table 85. Global Neuroendocrine Tumor Drug Revenue by Type (2023-2028) & (USD Million)
Table 86. Global Neuroendocrine Tumor Drug Price by Type (2017-2022) & (USD/Pcs)
Table 87. Global Neuroendocrine Tumor Drug Price by Type (2023-2028) & (USD/Pcs)
Table 88. Global Neuroendocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 89. Global Neuroendocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 90. Global Neuroendocrine Tumor Drug Revenue by Application (2017-2022) & (USD Million)
Table 91. Global Neuroendocrine Tumor Drug Revenue by Application (2023-2028) & (USD Million)
Table 92. Global Neuroendocrine Tumor Drug Price by Application (2017-2022) & (USD/Pcs)
Table 93. Global Neuroendocrine Tumor Drug Price by Application (2023-2028) & (USD/Pcs)
Table 94. North America Neuroendocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)
Table 95. North America Neuroendocrine Tumor Drug Sales by Country (2023-2028) & (K Pcs)
Table 96. North America Neuroendocrine Tumor Drug Revenue by Country (2017-2022) & (USD Million)
Table 97. North America Neuroendocrine Tumor Drug Revenue by Country (2023-2028) & (USD Million)
Table 98. North America Neuroendocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 99. North America Neuroendocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 100. North America Neuroendocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 101. North America Neuroendocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 102. Europe Neuroendocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)
Table 103. Europe Neuroendocrine Tumor Drug Sales by Country (2023-2028) & (K Pcs)
Table 104. Europe Neuroendocrine Tumor Drug Revenue by Country (2017-2022) & (USD Million)
Table 105. Europe Neuroendocrine Tumor Drug Revenue by Country (2023-2028) & (USD Million)
Table 106. Europe Neuroendocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 107. Europe Neuroendocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 108. Europe Neuroendocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 109. Europe Neuroendocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 110. Asia-Pacific Neuroendocrine Tumor Drug Sales by Region (2017-2022) & (K Pcs)
Table 111. Asia-Pacific Neuroendocrine Tumor Drug Sales by Region (2023-2028) & (K Pcs)
Table 112. Asia-Pacific Neuroendocrine Tumor Drug Revenue by Region (2017-2022) & (USD Million)
Table 113. Asia-Pacific Neuroendocrine Tumor Drug Revenue by Region (2023-2028) & (USD Million)
Table 114. Asia-Pacific Neuroendocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 115. Asia-Pacific Neuroendocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 116. Asia-Pacific Neuroendocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 117. Asia-Pacific Neuroendocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 118. South America Neuroendocrine Tumor Drug Sales by Country (2017-2022) & (K Pcs)
Table 119. South America Neuroendocrine Tumor Drug Sales by Country (2023-2028) & (K Pcs)
Table 120. South America Neuroendocrine Tumor Drug Revenue by Country (2017-2022) & (USD Million)
Table 121. South America Neuroendocrine Tumor Drug Revenue by Country (2023-2028) & (USD Million)
Table 122. South America Neuroendocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 123. South America Neuroendocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 124. South America Neuroendocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 125. South America Neuroendocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 126. Middle East & Africa Neuroendocrine Tumor Drug Sales by Region (2017-2022) & (K Pcs)
Table 127. Middle East & Africa Neuroendocrine Tumor Drug Sales by Region (2023-2028) & (K Pcs)
Table 128. Middle East & Africa Neuroendocrine Tumor Drug Revenue by Region (2017-2022) & (USD Million)
Table 129. Middle East & Africa Neuroendocrine Tumor Drug Revenue by Region (2023-2028) & (USD Million)
Table 130. Middle East & Africa Neuroendocrine Tumor Drug Sales by Type (2017-2022) & (K Pcs)
Table 131. Middle East & Africa Neuroendocrine Tumor Drug Sales by Type (2023-2028) & (K Pcs)
Table 132. Middle East & Africa Neuroendocrine Tumor Drug Sales by Application (2017-2022) & (K Pcs)
Table 133. Middle East & Africa Neuroendocrine Tumor Drug Sales by Application (2023-2028) & (K Pcs)
Table 134. Neuroendocrine Tumor Drug Raw Material
Table 135. Key Manufacturers of Neuroendocrine Tumor Drug Raw Materials
Table 136. Direct Channel Pros & Cons
Table 137. Indirect Channel Pros & Cons
Table 138. Neuroendocrine Tumor Drug Typical Distributors
Table 139. Neuroendocrine Tumor Drug Typical Customers
List of Figures
Figure 1. Neuroendocrine Tumor Drug Picture
Figure 2. Global Neuroendocrine Tumor Drug Revenue Market Share by Type in 2021
Figure 3. mTOR Protein Inhibitors
Figure 4. Tyrosine Kinase 3 Inhibitors
Figure 5. Somatostatin Receptor Antagonists
Figure 6. Growth Hormone Releasing Factor Antagonists
Figure 7. Somatostatin Receptor Agonists
Figure 8. Others
Figure 9. Global Neuroendocrine Tumor Drug Revenue Market Share by Application in 2021
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Global Neuroendocrine Tumor Drug Revenue, (USD Million) & (K Pcs): 2017 & 2021 & 2028
Figure 14. Global Neuroendocrine Tumor Drug Revenue and Forecast (2017-2028) & (USD Million)
Figure 15. Global Neuroendocrine Tumor Drug Sales (2017-2028) & (K Pcs)
Figure 16. Global Neuroendocrine Tumor Drug Price (2017-2028) & (USD/Pcs)
Figure 17. Global Neuroendocrine Tumor Drug Production Capacity (2017-2028) & (K Pcs)
Figure 18. Global Neuroendocrine Tumor Drug Production Capacity by Geographic Region: 2022 VS 2028
Figure 19. Neuroendocrine Tumor Drug Market Drivers
Figure 20. Neuroendocrine Tumor Drug Market Restraints
Figure 21. Neuroendocrine Tumor Drug Market Trends
Figure 22. Global Neuroendocrine Tumor Drug Sales Market Share by Manufacturer in 2021
Figure 23. Global Neuroendocrine Tumor Drug Revenue Market Share by Manufacturer in 2021
Figure 24. Neuroendocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 25. Top 3 Neuroendocrine Tumor Drug Manufacturer (Revenue) Market Share in 2021
Figure 26. Top 6 Neuroendocrine Tumor Drug Manufacturer (Revenue) Market Share in 2021
Figure 27. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2017-2028)
Figure 28. Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2017-2028)
Figure 29. North America Neuroendocrine Tumor Drug Revenue (2017-2028) & (USD Million)
Figure 30. Europe Neuroendocrine Tumor Drug Revenue (2017-2028) & (USD Million)
Figure 31. Asia-Pacific Neuroendocrine Tumor Drug Revenue (2017-2028) & (USD Million)
Figure 32. South America Neuroendocrine Tumor Drug Revenue (2017-2028) & (USD Million)
Figure 33. Middle East & Africa Neuroendocrine Tumor Drug Revenue (2017-2028) & (USD Million)
Figure 34. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2017-2028)
Figure 35. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2017-2028)
Figure 36. Global Neuroendocrine Tumor Drug Price by Type (2017-2028) & (USD/Pcs)
Figure 37. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2017-2028)
Figure 38. Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2017-2028)
Figure 39. Global Neuroendocrine Tumor Drug Price by Application (2017-2028) & (USD/Pcs)
Figure 40. North America Neuroendocrine Tumor Drug Sales Market Share by Type (2017-2028)
Figure 41. North America Neuroendocrine Tumor Drug Sales Market Share by Application (2017-2028)
Figure 42. North America Neuroendocrine Tumor Drug Sales Market Share by Country (2017-2028)
Figure 43. North America Neuroendocrine Tumor Drug Revenue Market Share by Country (2017-2028)
Figure 44. United States Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Canada Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Mexico Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Europe Neuroendocrine Tumor Drug Sales Market Share by Type (2017-2028)
Figure 48. Europe Neuroendocrine Tumor Drug Sales Market Share by Application (2017-2028)
Figure 49. Europe Neuroendocrine Tumor Drug Sales Market Share by Country (2017-2028)
Figure 50. Europe Neuroendocrine Tumor Drug Revenue Market Share by Country (2017-2028)
Figure 51. Germany Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific Neuroendocrine Tumor Drug Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Neuroendocrine Tumor Drug Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific Neuroendocrine Tumor Drug Sales Market Share by Region (2017-2028)
Figure 59. Asia-Pacific Neuroendocrine Tumor Drug Revenue Market Share by Region (2017-2028)
Figure 60. China Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Korea Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia Neuroendocrine Tumor Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia Neuroendocrine Tumor Drug Revenu
Global 5-Fluorouracil Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 76
The global 5-Fluorouracil market was valued at US$ 283 million in 2023 and is anticipated to reach US$ 487.9 million by 2030, witnessing a CAGR of 4.3% during The forecast period 2024-2030.
North American market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by ......
Global Carboplatin Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 79
The global Carboplatin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % d......
Global Neutropenia Drugs Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 96
The global Neutropenia Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated to increa......
Global Small Molecule Cancer Drug Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Small Molecule Cancer Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated ......
Global Capecitabine Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 80
Capecitabine is an orally-administered chemotherapeutic agent used in The treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in The tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blo......
Global Oxaliplatin Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 104
Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy The third stage colon cancer after resecting primary tumor completely.
In this report, only The finished drug is covered, exclude API.
The global Oxaliplatin market was valued at US$ 897.5 million in 2023 and is anticipated to reach US$ 1641.5 million by 2030, witnessing a CAGR of 8.9% duri......
Global Cancer Treatment Drugs Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 158
According to our LPI (LP Information) latest study, the global Cancer Treatment Drugs market size was valued at US$ 174990 million in 2023. With growing demand in downstream market, the Cancer Treatment Drugs is forecast to a readjusted size of US$ 322540 million by 2030 with a CAGR of 9.1% during review period.
The research report highlights the growth potential of the global Cancer Treatment Drugs market. Cancer Treatment Drugs are expected to show stable growth in the future market. H......
Global Capecitabine Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 93
According to our LPI (LP Information) latest study, the global Capecitabine market size was valued at US$ 1003.9 million in 2023. With growing demand in downstream market, the Capecitabine is forecast to a readjusted size of US$ 975.1 million by 2030 with a CAGR of -0.4% during review period.
The research report highlights the growth potential of the global Capecitabine market. Capecitabine are expected to show stable growth in the future market. However, product differentiation, reducin......
Global Methotrexate Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 95
According to our LPI (LP Information) latest study, the global Methotrexate market size was valued at US$ 506 million in 2023. With growing demand in downstream market, the Methotrexate is forecast to a readjusted size of US$ 613.9 million by 2030 with a CAGR of 2.8% during review period.
The research report highlights the growth potential of the global Methotrexate market. Methotrexate are expected to show stable growth in the future market. However, product differentiation, reducing co......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
